Ephedra and the FDA

DSpace/Manakin Repository

Ephedra and the FDA

Citable link to this page

. . . . . .

Title: Ephedra and the FDA
Author: Ehlers, Brandi E.
Citation: Ephedra and the FDA (2001 Third Year Paper)
Full Text & Related Files:
Abstract: The adverse events experienced after ingesting ephedra and other dietary supplements have demonstrated the need for FDA intervention. The FDA has an important role to play in safeguarding the health and safety of the American public. The FDA has been criticized as contravening the Congressional intent underlying DSHEA because of its attempts to regulate the dietary supplement industry, when in fact, the FDA has not overstepped its bounds. The agency has only taken the measures it felt necessary to protect the public and "implement a complex and ambiguous law." However, the FDA does need to focus on more effective procedures and systems for collecting adverse event reports and could take additional steps toward public awareness. In order for the FDA to address the overall problems with the regulating the dietary supplement industry efficiently and effectively, they will need additional funding.
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:8852148

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters